Project Details
Description
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
| Status | Finished |
|---|---|
| Effective start/end date | 12/1/17 → 11/30/22 |
Funding
- BIG TEN CANCER RESEARCH CONSORTIUM
- MERCK AND CO INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.